This cohort study examines the association between increasing tumor mutation burden (TMB) levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with non–small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and lung cancer.